-
Something wrong with this record ?
Novel Strategies in Transplantation: Genetic Engineering and Vascularized Composite Allotransplantation
M. Kauke-Navarro, OF. Noel, L. Knoedler, S. Knoedler, AC. Panayi, VA. Stoegner, L. Huelsboemer, B. Pomahac
Language English Country United States
Document type Journal Article, Review
- MeSH
- Genetic Engineering MeSH
- Transplantation, Homologous MeSH
- Immunosuppressive Agents therapeutic use MeSH
- Humans MeSH
- Graft Rejection prevention & control MeSH
- Organ Transplantation * MeSH
- Vascularized Composite Allotransplantation * methods MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
INTRODUCTION: Despite the clinical success in vascularized composite allotransplantation (VCA), systemic immunosuppression remains necessary to prevent allograft rejection. Even with potent immunosuppressive regimens (tacrolimus, mycophenolate mofetil, and steroids), most patients experience several rejection episodes, often within the same year. The risk of systemic side effects must constantly be weighed against the risk of under-immunosuppression and, thus, acute and chronic rejection. In this context, genomic editing has emerged as a potential tool to minimize the need for toxic immunosuppressive regimens and has gained attention in the fields of solid organ transplantation and xenotransplantation. This strategy may also be relevant for the future of VCA. METHODS: We discuss the topic of genetic engineering and review recent developments in this field that justify investigating tools such as clustered regularly interspaced short palindromic repeats/Cas9 in the context of VCA. RESULTS: We propose specific strategies for VCA based on the most recent gene expression data. This includes the well-known strategy of tolerance induction. Specifically, targeting the interaction between antigen-presenting cells and recipient-derived T cells by CD40 knockout may be effective. The novelty for VCA is a discovery that donor-derived T lymphocytes may play a special role in allograft rejection of facial transplants. We suggest targeting these cells prior to transplantation (e.g., by ex vivo perfusion of the transplant) by knocking out genes necessary for the long-term persistence of donor-derived immune cells in the allograft. CONCLUSION: Despite the demonstrated feasibility of VCA in recent years, continued improvements to immunomodulatory strategies using tools like clustered regularly interspaced short palindromic repeats/Cas9 could lead to the development of approaches that mitigate the limitations associated with rejection of this life-giving procedure.
Department of Surgery Brigham and Women's Hospital Harvard Medical School Boston Massachusetts
Institute of Musculoskeletal Medicine University Hospital Muenster Münster Germany
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24003183
- 003
- CZ-PrNML
- 005
- 20240509113208.0
- 007
- ta
- 008
- 240220e20230708xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jss.2023.04.028 $2 doi
- 035 __
- $a (PubMed)37429217
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kauke-Navarro, Martin $u Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Division of Plastic and Reconstructive Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, Connecticut
- 245 10
- $a Novel Strategies in Transplantation: Genetic Engineering and Vascularized Composite Allotransplantation / $c M. Kauke-Navarro, OF. Noel, L. Knoedler, S. Knoedler, AC. Panayi, VA. Stoegner, L. Huelsboemer, B. Pomahac
- 520 9_
- $a INTRODUCTION: Despite the clinical success in vascularized composite allotransplantation (VCA), systemic immunosuppression remains necessary to prevent allograft rejection. Even with potent immunosuppressive regimens (tacrolimus, mycophenolate mofetil, and steroids), most patients experience several rejection episodes, often within the same year. The risk of systemic side effects must constantly be weighed against the risk of under-immunosuppression and, thus, acute and chronic rejection. In this context, genomic editing has emerged as a potential tool to minimize the need for toxic immunosuppressive regimens and has gained attention in the fields of solid organ transplantation and xenotransplantation. This strategy may also be relevant for the future of VCA. METHODS: We discuss the topic of genetic engineering and review recent developments in this field that justify investigating tools such as clustered regularly interspaced short palindromic repeats/Cas9 in the context of VCA. RESULTS: We propose specific strategies for VCA based on the most recent gene expression data. This includes the well-known strategy of tolerance induction. Specifically, targeting the interaction between antigen-presenting cells and recipient-derived T cells by CD40 knockout may be effective. The novelty for VCA is a discovery that donor-derived T lymphocytes may play a special role in allograft rejection of facial transplants. We suggest targeting these cells prior to transplantation (e.g., by ex vivo perfusion of the transplant) by knocking out genes necessary for the long-term persistence of donor-derived immune cells in the allograft. CONCLUSION: Despite the demonstrated feasibility of VCA in recent years, continued improvements to immunomodulatory strategies using tools like clustered regularly interspaced short palindromic repeats/Cas9 could lead to the development of approaches that mitigate the limitations associated with rejection of this life-giving procedure.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a rejekce štěpu $x prevence a kontrola $7 D006084
- 650 12
- $a vaskularizovaná kompozitní alotransplantace $x metody $7 D063986
- 650 _2
- $a homologní transplantace $7 D014184
- 650 12
- $a transplantace orgánů $7 D016377
- 650 _2
- $a imunosupresiva $x terapeutické užití $7 D007166
- 650 _2
- $a genetické inženýrství $7 D005818
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Noel, Olivier F $u Division of Plastic and Reconstructive Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, Connecticut
- 700 1_
- $a Knoedler, Leonard $u Department of Plastic, Hand and Reconstructive Surgery, University Hospital Regensburg, Regensburg, Germany
- 700 1_
- $a Knoedler, Samuel $u Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
- 700 1_
- $a Panayi, Adriana C $u Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
- 700 1_
- $a Stoegner, Viola A $u Division of Plastic and Reconstructive Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, Connecticut; Department of Plastic, Aesthetic, Hand and Reconstructive Surgery, Burn Center, Hannover Medical School, Hannover, Germany
- 700 1_
- $a Huelsboemer, Lioba $u Division of Plastic and Reconstructive Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, Connecticut; Institute of Musculoskeletal Medicine, University Hospital Muenster, Münster, Germany
- 700 1_
- $a Pomahac, Bohdan $u Division of Plastic and Reconstructive Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, Connecticut. Electronic address: bohdan.pomahac@yale.edu
- 773 0_
- $w MED00002957 $t The Journal of surgical research $x 1095-8673 $g Roč. 291 (20230708), s. 176-186
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37429217 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240220 $b ABA008
- 991 __
- $a 20240509113202 $b ABA008
- 999 __
- $a ok $b bmc $g 2088839 $s 1212923
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 291 $c - $d 176-186 $e 20230708 $i 1095-8673 $m The Journal of surgical research $n J Surg Res $x MED00002957
- LZP __
- $a Pubmed-20240220